Biopharmaceutical company developing Levosimendan for heart failure
1 AI-extracted insight from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Tenax Therapeutics Inc..
The 1 sources with the most insights about Tenax Therapeutics Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
The speaker notes that it is a hard stock to short because the name is TENX, while researching its clinical data and mechanism of action.
The speaker notes that it is a hard stock to short because the name is TENX, while researching its clinical data and mechanism of action.
Other assets that creators frequently mention in the same content as Tenax Therapeutics Inc..
The most active sources covering Tenax Therapeutics Inc. (TENX) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 1 AI-extracted insight about Tenax Therapeutics Inc. (TENX) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Tenax Therapeutics Inc. (TENX) most frequently also discuss NVDA, INTC, MU, PLTR, QBTS. See the "Discussed alongside" section above for full asset pages.